GSK · Pharma and healthcare · one day
GSK (GSK): news on Friday 6 November 2026
News from the 24 hours to Friday morning, 6 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mainly about a cancer drug approval, liver pipeline updates and a $100M HIV care pledge from ViiV, which lean positive. The share price was flat and a legal chief succession was routine.
What drove it
- Jemperli approval
- ViiV HIV funding
- liver portfolio data
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sat 31 Oct | +4.0 | 12 |
| Mon 2 Nov | +8.0 | 3 |
| Tue 3 Nov | +2.7 | 6 |
| Wed 4 Nov | +5.0 | 14 |
| Thu 5 Nov | +5.0 | 11 |
| Fri 6 Nov | +4.5 | 8 |
6 stories · 8 headlines · strongest first
Pharma and healthcare on 6 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| ViiV Healthcare sets aside $100m for American HIV care networks +5.02 headlines today · ViiV Healthcare announced a $100m commitment toward HIV care networks at local level across the US. | ||
| +5.0 | Subsidiary ViiV pledging funds for HIV care networks | |
| +5.0 | Subsidiary ViiV pledging funds for HIV care networks | |
| GSK share price moves +0.82 headlines today · 6 in all, since 5 November · Pieces report GSK shares trading flat at 1,890p. | ||
| +0.8 | Flat trading with some buying support | |
| 0.0 | Routine share price quote showing no movement | |
| GSK valuation after Jemperli approval +8.31 headline today · A piece considers GSK's valuation following the Jemperli approval. | ||
| +8.3 | Regulatory approval for cancer drug supports valuation view | |
| At AASLD 2026, GSK presents its liver portfolio +5.01 headline today · GSK showcased progress in its liver portfolio at the AASLD meeting. | ||
| +5.0 | Company presenting liver pipeline progress at medical conference | |
| GSK buzz in UK pharma stocks discussed +2.51 headline today · A commentary looks at interest in GSK shares. | ||
| +2.5 | Commentary on investor interest in the shares | |
| GSK recruits new general counsel 0.01 headline today · GSK is hiring a new legal chief as its long-serving general counsel prepares to leave. | ||
| 0.0 | Routine succession of general counsel, orderly handover | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.